Effects Of Carnosine On Autism

Clinical Trials Of ?Effects Of Carnosine Supplementation On Serotonin, Glutamate And Disease Severity In Children With Autism Disorder

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016061711689N4

Enrollment

Registered

2016-12-02

Start date

2016-06-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autism Disorder. autism disorders

Interventions

Intervention 1: Intervention group: Intake of Carnosine 500 mg capsule once a day with lunch, for 8 weeks. Intervention 2: Placebo group: Intake of Placebo capsule containing 500 mg of starch, which i

Intervention group: Intake of Carnosine 500 mg capsule once a day with lunch, for 8 weeks.

Placebo group: Intake of Placebo capsule containing 500 mg of starch, which is similar to Carnosine supplement in terms of dosage, color and size, once a day for 8 weeks.

Eligibility

Sex/Gender

All

Age

6 Years to 12 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: diagnosis of Autism by psychologist; age between 6 to 12 years old; unchanged method of medical treatment since two months before intervention and through out follow up time; not receiving other supplements; mental retardation. Exclusion criteria: consumption of any types of Chelator drugs in study duration; following of special diet; neurological diseases like epilepsy, Cerebral Palsy and...; all types of metabolic disorders; medical treatment method alteration during study period; adherence of supplement less than 75 percent.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Serotonin. Timepoint: at Beginning and eighth week of the study. Method of measurement: ELISA.;Glutamat. Timepoint: at Beginning and eighth week of the study. Method of measurement: HPLC.;Autism disorder severity. Timepoint: At Beginning and eighth week of the study. Method of measurement: GARS questionnaire.;Gastrointestinal disorders. Timepoint: At Beginning and eighth week of the study. Method of measurement: ROME3 questionnaire.;Sleep disorders. Timepoint: At Beginning and eighth week of the study. Method of measurement: CSHQ questionnaire.;Food intake. Timepoint: At Beginning and fourth week and eighth week of the study. Method of measurement: 3 days food intake.	—

Measure

Time frame

Serotonin. Timepoint: at Beginning and eighth week of the study. Method of measurement: ELISA.;Glutamat. Timepoint: at Beginning and eighth week of the study. Method of measurement: HPLC.;Autism disorder severity. Timepoint: At Beginning and eighth week of the study. Method of measurement: GARS questionnaire.;Gastrointestinal disorders. Timepoint: At Beginning and eighth week of the study. Method of measurement: ROME3 questionnaire.;Sleep disorders. Timepoint: At Beginning and eighth week of the study. Method of measurement: CSHQ questionnaire.;Food intake. Timepoint: At Beginning and fourth week and eighth week of the study. Method of measurement: 3 days food intake.

—

Secondary

Measure	Time frame
Phisical activity. Timepoint: At Beginning and eighth week of the study. Method of measurement: international phisical activity questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Sorayya kheirouri

Nutrition Sciences Faculty, Tabriz University of Medical Sciences

kheirouris@tbzmed.ac.ir+98 41 3335 7580

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026